PLD1 and neoplasm: Therefore, it is plausible that those patients with tumours positive for ER and PLD1 will respond to combined anti-hormone and rapamycin-based therapies; that combination has been successful in inhibiting the proliferation of breast cancer cell lines (Boulay et al, 2005).